DOCSLIB.ORG

Therapy Strategies in Psoriatic Arthritis L.C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapy Strategies in Psoriatic Arthritis L.C Therapy strategies in psoriatic arthritis L.C. Coates Leeds Institute of Rheumatic and ABSTRACT RCT and the associated potential risks Musculoskeletal Medicine, University Psoriatic arthritis (PsA) is a heteroge- of these should be elucidated. of Leeds, UK, and Leeds Musculoskeletal neous condition with a myriad of differ- Currently, most clinical practice is to Biomedical Research Unit, Leeds ent clinical presentations. It commonly use a step up approach to minimise Teaching Hospitals Trust, UK; Division of Allergy, Immunology and affects the skin and musculoskeletal potential toxicity, as chosen by the ex- Rheumatology, University of Rochester system causing psoriasis, peripheral pert committee drafting the European Medical Center, Rochester, New York, USA. arthritis, axial arthritis, enthesitis and League Against Rheumatism (EULAR) Laura C. Coates, MBChB, MRCP, PhD dactylitis. Many patients also have re- recommendations for PsA. The com- Please address correrspondence to: lated conditions, such as those within mittee recommends initial use of sin- Dr Laura Coates, the metabolic syndrome and associ- gle DMARDs, followed by a second University of Leeds, ated spondyloarthritis (SpA) conditions DMARD either in series or in combina- Chapel Allerton Hospital, 2nd Floor, including inflammatory bowel disease tion, or an escalation to biologic therapy, Harehills Lane, and uveitis. Any therapeutic strategy depending on the presence or absence of Leeds LS7 4SA, United Kingdom. must be tailored to the individual pa- poor prognostic markers (2). The mark- E-mail: [email protected] tient, taking into account her/his com- ers included are based on prognosis Received and accepted on August 20, 2015. plete clinical presentation and comor- studies investigating predictors of sub- Clin Exp Rheumatol 2015; 33 (Suppl. 93): bidities. New treatment recommenda- sequent joint damage and functional S70-S72. tions from the Group for Research and impairment and include raised inflam- © Copyright CLINICAL AND Assessment of Psoriasis and Psoriatic matory markers, polyarticular involve- EXPERIMENTAL RHEUMATOLOGY 2015. Arthritis (GRAPPA) provide evidence ment, previous joint damage and func- based recommendations on effective tional impairment. Key words: psoriatic arthritis, therapies for the management of each therapy strategies different manifestation of PsA, and how Early intervention treatment may be affected by comorbidi- Observational data have indicated that ties (1). However, the limited evidence a longer delay in diagnosis is associated comparing different treatment strategies with poorer outcomes in PsA. A shorter in PsA is recognised as a limitation in duration of symptoms prior to diagnosis these recommendations and further in- was associated with improved disease formation is detailed below. activity outcomes at 5-year follow-up (3) in patients in a Swedish early PsA Treatment plans: step up versus registry. Tillett et al. identified that a step down? >12 months delay in diagnosis was a Research into therapeutic strategies significant predictor of functional im- in PsA is limited. When using dis- pairment at 10 years (4). Haroon et al. ease-modifying anti-rheumatic drugs found in 283 patients with PsA that (DMARDs), one of the common ques- patients with more than 6 months of tions, more widely studied in RA, in- symptoms prior to a diagnosis are more volves step up versus step down thera- likely to have erosive peripheral joint py. In step up, one therapy is prescribed disease, arthritis mutilans, joint deform- initially, before moving onto combined ity, functional impairment and sacroili- therapies if there is an incomplete re- itis, and were significantly less likely to sponse (or none) according to defined achieve a drug free remission (5). criteria. By contrast, step down therapy The above evidence supports a likely directs that treatment is initiated aggres- benefit for early intervention in PsA, sively with combination therapies, and but prospective clinical trial evidence these are gradually reduced if patients is limited. The only trial assessing im- Competing interests: L.C. Coates is achieve a predefined goal. To date, no mediate versus delayed DMARD pre- funded by the NIHR as a Clinical Lecturer, and has received research research in PsA has compared these ap- scription did not show a significant dif- funding and/or honoraria from Abbvie, proaches. The potential benefits of early ference at 6 months but it was markedly Boehringer-Ingelheim, Pfizer, UCB, combination or aggressive treatment underpowered with only 35 patients in Celgene, Janssen and MSD. strategies should be examined in an the entire study. This trial also was an S-70 Therapy strategies in psoriatic arthritis/ L.C. Coates open label study and patients were trat- principally looking for “strategic studies the primary search: “strategic studies ed with relatively low doses of metho- that compared a therapy steered towards that compared a therapy steered towards trexate (10 mg/week) which may not a prespecified treatment target versus a a prespecified treatment target versus be effective. There has been one large conventional non-steered approach”. At a conventional non-steered approach”. randomised controlled trial (RCT) of a the time, they identified that there were The Tight Control of Psoriatic Arthritis tumour necrosis factor inhibitor (TNFi) no studies in any of the SpA, including (TICOPA) study recruited 206 patients in early PsA which showed higher than PsA that fulfilled this description. They with recent onset PsA. They were ran- expected responses in both the metho- did find a small number of studies where domised 1:1 to tight control or standard trexate (control) group and the TNFi treatment was changed based on a pre- care. Patients in the tight control arm group (6), potentially suggesting a bet- specified target, but not with a compari- were reviewed every 4 weeks by the ter outcome when therapies are used son group. The majority of these were research rheumatologists, and treatment earlier in the course of the disease. large RCTs of TNF inhibitors in PsA was escalated if they did not meet MDA However, this study was also open label which had “early escape” arms if a mini- criteria. The study used a treatment al- in comparison to the majority of TNFi mal improvement in joint counts was not gorithm of methotrexate, combination trials in established disease which re- seen at 12 or 16 weeks (15). DMARDs and biologic agents in a step- port double-blind outcomes. There are One issue raised by the EULAR litera- up design. Patients in the standard care obvious cautions in comparing out- ture review and subsequent recommen- arm were reviewed every 12 weeks and comes between two separate trials, so dations on treatment to target in SpA were treated by their usual rheumatolo- again this evidence is inconclusive. (16) was the difficulty in identifying an gist. There were no limitations on their appropriate target. The EULAR task- care, except compliance with UK NICE Treatment to target force recommended remission as the criteria for the use of TNF inhibitors in The concept of “tight control” or “treat- main target for all SpA with low disease PsA which was standard across both to-target” was developed in rheumatoid activity as an alternative target (16). At trial arms (21). arthritis (RA) following clinical and that time, there are were remission crite- The odds of achieving ACR20, the pri- imaging studies suggesting that ac- ria validated in PsA; The best validated mary outcome, at 48 weeks were sig- tive inflammation predicted future joint criteria defining low disease activity nificantly higher in the tight control arm damage (7, 8). A pivotal study was the and remission combined are the mini- (OR 1.91, p=0.0392) using intention to Tight Control of RA (TICORA) study mal disease activity (MDA) criteria for treat analysis. The odds of achieving which showed a significant benefit after PsA (17). These criteria do not provide a ACR50, ACR70 and PASI75 also were 18 months of therapy despite only using disease activity score, only a definition significantly higher for the tight control conventional DMARDs and corticos- of a low disease state. They have been group. Greater improvements were also teroids. Patients in the tight control arm validated in observational cohorts and seen with tight control in patient-report- who continued to have a DAS>2.4 at in RCT data showing responsiveness to ed outcomes including physical func- their monthly visits had their DMARD change, agreement with treatment deci- tion (HAQ), quality of life (PsQOL) therapy escalated and were given addi- sions (18), differentiation between drug and also BASDAI and BASFI for those tional systemic or intra-articular steroids and placebo and correlation with other with axial disease. No difference was up to 120 mg per visit. At the end of the outcome measures. seen in radiographic progression be- study, 82% of tight control patients met These analyses also confirmed prog- tween the two arms; however, the mean the EULAR good response compared to nostic value with patients in consistent change in modified van der Heijde- 44% of controls (p<0.0001) (9). Further MDA having less progression in clinical Sharp score was zero in both groups. studies confirmed the benefit of treating joint damage (18) and radiographic out- The tight control arm was associated to an objective target including using come (19). Proposed definitions of low with increased rates of adverse events computer designed algorithms (10, 11) disease activity have also now been de- and serious adverse events, which may and this approach is now recommended veloped for the new composite measures have been due to the more rapid escala- in the UK as standard of care in the clinic in PsA: the PASDAS, the GRACE index tion of DMARD therapy (22). with newly diagnosed RA patients (12). and the CPDAI (20) but these have not Following the success in RA, the con- yet been validated. The other key con- Reduction or withdrawal of therapy cept of treat to target developed in the sideration for routine clinical use is fea- Given the excellent responses with spondyloarthritides (SpA).
Load more

Recommended publications
  • Rheuma.Stamp Line&Box
    Arthritis Mutilans: A Report from the GRAPPA 2012 Annual Meeting Vinod Chandran, Dafna D. Gladman, Philip S. Helliwell, and Björn Gudbjörnsson ABSTRACT. Arthritis mutilans is often described as the most severe form of psoriatic arthritis. However, a widely agreed on definition of the disease has not been developed. At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members hoped to agree on a definition of arthritis mutilans and thus facilitate clinical and molecular epidemiological research into the disease. Members discussed the clinical features of arthritis mutilans and defini- tions used by researchers to date; reviewed data from the ClASsification for Psoriatic ARthritis study, the Nordic psoriatic arthritis mutilans study, and the results of a premeeting survey; and participated in breakout group discussions. Through this exercise, GRAPPA members developed a broad consensus on the features of arthritis mutilans, which will help us develop a GRAPPA-endorsed definition of arthritis mutilans. (J Rheumatol 2013;40:1419–22; doi:10.3899/ jrheum.130453) Key Indexing Terms: OSTEOLYSIS ANKYLOSIS PENCIL-IN-CUP SUBLUXATION FLAIL JOINT ARTHRITIS MUTILANS Psoriatic arthritis (PsA) is an inflammatory musculoskeletal gists as a severe destructive form of PsA, a precise disease specifically associated with psoriasis. Moll and definition has not yet been universally accepted. The earliest Wright defined PsA as “psoriasis associated with inflam- definition of arthritis mutilans was provided
    [Show full text]
  • Psoriatic Arthritis Howard Duncan
    Henry Ford Hospital Medical Journal Volume 13 | Number 2 Article 6 6-1965 Psoriatic Arthritis Howard Duncan Darrell Oberg William R. Eyler Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Duncan, Howard; Oberg, Darrell; and Eyler, William R. (1965) "Psoriatic Arthritis," Henry Ford Hospital Medical Bulletin : Vol. 13 : No. 2 , 173-181. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol13/iss2/6 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. Henry Ford Hosp. Med. Bull. Vol. 13, June, 1965 PSORIATIC ARTHRITIS* HOWARD DUNCAN, M.D.,** DARRELL OBERG, M.D.,** AND WILLIAM R. EYLER, M.D.*** Dr. Howard Duncan. It is apparent from these meetings that rheumatologists are not alone in having troubles with dissension amongst the hierarchy in arriving at a decision as to whether a disease exists or not. The problem is the relationship between arthritis and psoriasis. Our first approach will be to demonstrate that there is an entity "psoriatic arthritis" which is distinct from rheumatoid arthritis with psoriasis. I'll ask Dr. Oberg to illustrate the situation. Dr. Darrell Oberg. Our patient is a 49 year old white female who was first .seen in this hospital in 1960, at which time she was admitted with malignant hypertension, which has subsequently been controlled by treatment prescribed in the Hypertension Division.
    [Show full text]
  • Spondyloarthropathies and Reactive Arthritis
    RHEUMATOLOGY SPONDYLOARTHRITIS ROBERT L. DIGIOVANNI, DO, FACOI PROGRAM DIRECTOR LMC RHEUMATOLOGY FELLOWSHIP [email protected] DISCLOSURES •NONE SERONEGATIVE SPONDYLOARTHROPATHIES SLIDES PREPARED BY GENE JALBERT, DO SENIOR RHEUMATOLOGY FELLOW THE SPONDYLOARTHROPATHIES: • Ankylosing Spondylitis (A.S.) • Non-radiographic Axial spondyloarthropathies (nr-axSpA) • Psoriatic Arthritis (PsA) • Inflammatory Bowel Disease Associated (Enteropathic) • Crohn and Ulcerative Colitis • +/- Microscopic colitis • Reactive Arthritis (ReA) • Juvenile-Onset SpA • Others: Bechet’s dz, Celiac, Whipples, pouchitis. THE FAMOUS VENN DIAGRAM: SPONDYLOARTHROPATHY: • First case of Axial SpA was reported in 1691 however some believe Ramses II has A.S. • 2.4 million adults in the United States have Seronegative SpA • Compare with RA, which affects about 1.3 million Americans • Prevalence variation for A.S.: Europe (0.12-1%), Asia (0.17%), Latin America (0.1%), Africa (0.07%), USA (0.34%). • Pathophysiology in general: • Responsible Interleukins: IL-12, IL17, IL-22, and IL23. SPONDYLOARTHROPATHY: • Axial SpA: • Radiographic (Sacroiliitis seen on X- ray) • No Radiographic features non- radiographic SpA (nr-SpA) • Nr-SpA was formally known as undifferentiated SpA • Peripheral SpA: • Enthesitis, dactylitis and arthritis • Eventually evolves into a specific diagnosis A.S., PsA, etc. • Can be a/w IBD, HLA-B27 positivity, uveitis SHARED CLINICAL FEATURES: • Axial joint disease (especially SI joints) • Asymmetrical Oligoarthritis (2-4 joints). • Dactylitis (Sausage
    [Show full text]
  • The Rheumatoid Thumb
    THE RHEUMATOID THUMB BY ANDREW L. TERRONO, MD The thumb is frequently involved in patients with rheumatoid arthritis. Thumb postures can be grouped into a number of deformities. Deformity is determined by a complex interaction of the primary joint, the adjacent joints, and tendon function and integrity. Joints adjacent to the primarily affected one usually assume an opposite posture. If they do not, tendon ruptures should be suspected. Surgical treatment is individualized for each patient and each joint, with consideration given to adjacent joints. The treatment consists of synovectomy, capsular reconstruction, tendon reconstruction, joint stabilization, arthrodesis, or arthroplasty. Copyright © 2001 by the American Society for Surgery of the Hand he majority of patients with rheumatoid ar- ring between the various joints. Any alteration of thritis will develop thumb involvement.1,2,3 posture at one level has an effect on the adjacent joint. TThe deformities encountered in the rheuma- The 6 patterns of thumb postures described here, toid patient are varied and are the result of changes unfortunately, do not exhaust the deformities one taking place both intrinsically and extrinsically to the encounters in rheumatoid arthritis (Table 1). It is thumb. Synovial hypertrophy within the individual possible, for example, for the patient to stretch the thumb joints leads not only to destruction of articular supporting structures of a joint, causing a flexion, cartilage, but can also stretch out the supporting extension, or lateral deformity. However, instead of collateral ligaments and joint capsules. As a result, the adjacent joint assuming the opposite posture, it each joint can become unstable and react to the may assume an abnormal position secondary to a stresses applied to it both in function against the other tendon rupture.
    [Show full text]
  • Drug Class Review on Targeted Immune Modulators
    Drug Class Review on Targeted Immune Modulators Final Report December 2005 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Gerald Gartlehner, MD, MPH Richard A. Hansen, PhD Patricia Thieda, MA Beth Jonas, MD Kathleen N. Lohr, PhD Tim Carey, MD, MPH Produced by RTI-UNC Evidence-based Practice Center Cecil G. Sheps Center for Health Services Research University of North Carolina at Chapel Hill 725 Airport Road, CB# 7590 Chapel Hill, NC 27599-7590 Tim Carey, MD, MPH, Director Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Copyright © 2005 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved Final Report Drug Effectiveness Review Project TABLE OF CONTENTS List of Abbreviations ............................................................................................................................... 4 Introduction............................................................................................................................................... 6 Scope and Key Questions ............................................................................................................. 12 Methods
    [Show full text]
  • Clinical Presentation of Psoriatic Arthritis Among Sudanese: Hospital Based Study
    International Journal of Research Article Clinical Rheumatology Clinical presentation of psoriatic arthritis among sudanese: hospital based study Back ground: Psoriasis is a common papulo-squamous disorder affecting 2% of the population and Nasereldin Hamednalla Elasha is characterized by well demarcated red scaly plaques. Psoriatic Arthritis (PsA) may be defined as Hamednalla1,2,3,4, El nour an inflammatory arthritis which is seronegative for Rheumatoid Factor (RF) and enthesitis that is Mohammed El agib1, 2, Safi associated with psoriasis. The aims of our study is to identify different clinical presentations and Eldin Elnour Ali5, Mohammed types of psoriatic arthritis. Elmujtba Adam Essa*6 Methods: This is a descriptive cross sectional hospital based study conducted at Omdurman military 1Department of Internal Medicine and Rheumatology, Omdurman Military Hospital, hospital, Khartoum, Sudan, for a period of six months. The study included 96 patients confirm Omdurman, Khartoum, Sudan diagnosed by dermatologist as psoriasis, the data obtain with designed questionnaire contains the 2Department of Rheumatology, Sudan clinical presentations of the disease, lab result and radiological imaging, the study analyzed by SPSS Medical Specializations Board, Khartoum, v.20 by using one way a nova method to determine the P. value. Sudan 3Department of internal Medicine, Karary Results: From the total number of patients with Psoriasis, more than one third was psoriatic arthritis, University, Omdurman, Khartoum, Sudan 4Department of Internal Medicine, Ahfad 6% of patients with psoriatic arthritis were oligo-arthritis joint involvements, 14% were polyarthritis, university, Omdurman, Khartoum, Sudan 9% were distal inter phalangeal joint, 9% were spondylitis/sacroillitis and the remaining 5% were 5Department of Dermatology, Omdurman arthritis mutilants.
    [Show full text]
  • Project Plan – November 2016
    American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) Psoriatic Arthritis Guideline Project Plan – November 2016 PARTICIPANTS Core Oversight Team Veronica Richardson, NP Jasvinder Singh, MD, MPH (Principal Investigator, Jose Scher, MD Voting Panel Leader) Evan Siegel, MD James Reston, MD (Literature Review Leader) Michael Siegel, PhD Dafna Gladman, MD (Content Expert) Ingrid Steinkoenig Alexis Ogdie, MD, MSCE (Content Expert) Jessica Walsh, MD Gordon Guyatt, MD (GRADE Expert) Patient Panel Literature Review Team Eddie Applegate Helena Jonsson, MD Gail C. Richardson Amit Aakash Shah, MD, MPH Hilary Wilson Nancy Sullivan, BA Marat Turgunbaev, MD, MPH ACR Staff Robin Lane Voting Panel Amy S. Miller Chad Deal, MD Regina Parker Atul Deodhar, MD Deborah Desir, MD NPF Staff Maureen Dubreuil, MD Emily Boyd Jonathan Dunham, MD Elaine Husni, MD, MPH ECRI Institute Staff Sarah Kenny Karen Schoelles, MD Paula Marchetta, MD, MBA Phil Mease, MD Julie Miner, PT Christopher Ritchlin, MD, MPH Ben Smith, PA-C Abby Van Voorhees, MD Expert Panel Laura Coates, MD Marina Magrey, MD Joseph Merola, MD, MMSC Ben Nowell, PhD Ana-Maria Orbai, MD Soumya Reddy, MD 1 American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) Psoriatic Arthritis Guideline Project Plan – November 2016 1 2 ORGANIZATIONAL LEADERSHIP AND SUPPORT 3 4 This collaborative project of the American College of Rheumatology (ACR) and the National Psoriasis 5 Foundation has the broad objective of developing an evidence-based clinical practice guideline for the 6 management of psoriatic arthritis (PsA), not covering skin manifestations of psoriasis. 7 8 BACKGROUND 9 10 Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis.
    [Show full text]
  • A Systematic Approach to Differentiating Joint Disorders A
    MedicalContinuing Education PODIATRIC RADIOGRAPHY Objectives After completing this mate- rial the reader shall be able to: 1) List the radiographic criteria for systematically evaluating joints and joint disease. 2) Define: joint effusion, AA SystematicSystematic arthritis mutilans, and en- thesopathy. 3) List common joint dis- ApproachApproach toto orders that are associated with arthritis. 4) Explain the importance DifferentiatingDifferentiating of a lesion (erosion, for exam- ple) having either a well- defined or ill-defined margin. JointJoint DisordersDisorders 5) List target areas in the foot and calcaneus for com- X-rays can be an important mon arthritic disorders. 6) Distinguish between tool in confirming your the joint disorders (based diagnosis. on radiographic findings). Welcome to Podiatry Management’s CME Instructional program. Our journal has been approved as a sponsor of Contin- uing Medical Education by the Council on Podiatric Medical Education. You may enroll: 1) on a per issue basis (at $17.50 per topic) or 2) per year, for the special introductory rate of $109 (you save $66). You may submit the answer sheet, along with the other information requested, via mail, fax, or phone. In the near future, you may be able to submit via the Internet. If you correctly answer seventy (70%) of the questions correctly, you will receive a certificate attesting to your earned cred- its. You will also receive a record of any incorrectly answered questions. If you score less than 70%, you can retake the test at no additional cost. A list of states currently honoring CPME approved credits is listed on pg. 246. Other than those entities cur- rently accepting CPME-approved credit, Podiatry Management cannot guarantee that these CME credits will be acceptable by any state licensing agency, hospital, managed care organization or other entity.
    [Show full text]
  • Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis
    Psoriatic arthritis RMD Open: first published as 10.1136/rmdopen-2018-000656 on 13 August 2018. Downloaded from REVIEW Distinguishing rheumatoid arthritis from psoriatic arthritis Joseph F Merola,1 Luis R Espinoza,2 Roy Fleischmann3 To cite: Merola JF, Espinoza LR, ABSTRACT Key messages Fleischmann R. Distinguishing Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) rheumatoid arthritis from have key differences in clinical presentation, radiographic What is already known about this subject? psoriatic arthritis. RMD Open findings, comorbidities and pathogenesis to distinguish Rheumatoid arthritis (RA) and psoriatic arthritis 2018;4:e000656. doi:10.1136/ between these common forms of chronic inflammatory ► rmdopen-2018-000656 (PsA) are both common chronic inflammatory dis- arthritis. Joint involvement is typically, but not always, eases, and differentiation of these conditions can be asymmetric in PsA, while it is predominantly symmetric in challenging. ► Prepublication history for RA. Bone erosions, without new bone growth, and cervical this paper is available online. spine involvement are distinctive of RA, while axial spine To view these files, please visit What does this study add? involvement, psoriasis and nail dystrophy are distinctive ► We review key differences in clinical, serological, ra- the journal online (http://dx. doi. of PsA. Patients with PsA typically have seronegative test org/ 10. 1136/ rmdopen- 2018- diographic and pathogenic features of RA and PsA, findings for rheumatoid factor (RF) and cyclic citrullinated 000656). and provide practical guidance for achieving a cor- peptide (CCP) antibodies, while approximately 80% of rect diagnosis. Received 31 January 2018 patients with RA have positive findings for RF and CCP Revised 25 May 2018 antibodies.
    [Show full text]
  • Bilateral Total Hip Arthroplasty in a Rare Case of Multicentric Reticulohistiocytosis Balaji Saibaba, MS, Ramesh Kumar Sen, MS, Ashim Das, MD*, Aman Sharma, MD*
    Case Report Clinics in Orthopedic Surgery 2015;7:509-514 • http://dx.doi.org/10.4055/cios.2015.7.4.509 Bilateral Total Hip Arthroplasty in a Rare Case of Multicentric Reticulohistiocytosis Balaji Saibaba, MS, Ramesh Kumar Sen, MS, Ashim Das, MD*, Aman Sharma, MD* Departments of Orthopaedics and *Pathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India Multicentric reticulohistiocytosis (MRH) is a rare systemic disease, which commonly manifests as muco-cutaneous papulonodules and inflammatory erosive polyarthropathy. In this research, we report the clinical manifestations and management of a rare case of MRH with destructive arthropathy of bilateral hip joints and arthritis mutilans presenting with characteristic deformities. Disabling hip arthropathy that occurs secondary to MRH can be successfully managed with bilateral total hip arthroplasty (THA). Osteopenia and acetabular bone defects must be anticipated during THA. This case is reported due to its rare occurrence and because little literature has been published regarding THA in such patients. Keywords: Hip, Histiocytosis, Non-Langerhans-cell, Arthroplasty, Replacement Multicentric reticulohistiocytosis (MRH), which is also that had gradually been getting worse in both hip regions called lipoid dermato-arthropathy or lipoid rheumatism, for the past 4 years. He also had difficulty in walking is a rare multisystem disorder commonly presenting with unassisted, sitting, squatting and climbing stairs. He was variegated skin lesions and progressive destructive ar- a known case of histiocytosis, diagnosed and treated 18 thropathy. The exact incidence of the disease is obscure; years back for skin lesions. On general physical examina- with less than 200 cases described in the literature.1) The tion, the patient had deformities of bilateral hands—“opera etiology of MRH is unknown, probably immunological.
    [Show full text]
  • Psoriatic Arthritis: an Assessment of Clinical, Biochemical and Radiological Features in a Single-Centre South African Cohort
    RESEARCH Psoriatic arthritis: An assessment of clinical, biochemical and radiological features in a single-centre South African cohort A B Maharaj,1,2 MBBS, H Dip Int Med (SA), FCP (SA), Cert Rheumatol (SA); M Rajkaran,1 MB BCh, FCP (SA); J Govender,1 BSc Hons, MB ChB; K Maharaj,1 MB ChB, FCP (SA); N de Vries,2 MD, PhD; P P Tak,2 MD, PhD 1 Department of Internal Medicine, Prince Mshiyeni Memorial Hospital and School of Clinical Medicine, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa 2 Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Netherlands Corresponding author: A B Maharaj ([email protected]) Background. Although psoriatic arthritis (PsA) is a well-documented clinical entity, epidemiological, clinical and radiological studies of South African (SA) patients are scarce. Objectives. To assess clinical, biochemical and radiological features in a single-centre SA cohort. Methods. We conducted a prospective assessment of the clinical, biochemical and radiological features of 384 consecutive patients with PsA seen at the rheumatology clinic at Prince Mshiyeni Memorial Hospital, Durban, SA, between January 2007 and December 2013. Patients were assessed at enrolment and 6 months after enrolment. They were classified into five groups as described by Moll and Wright, being entered into the group that best described the clinical manifestations. Clinicopathological characteristics recorded at enrolment were age at the time of examination, racial background, personal and family medical history, age and symptoms at the onset of PsA, pattern of joint involvement, joint pain, and the relationship between joint pain and the onset of PsA.
    [Show full text]
  • MRI Bone Oedema Scores Are Higher in the Arthritis Mutilans Form Of
    Available online http://arthritis-research.com/content/11/1/R2 ResearchVol 11 No 1 article Open Access MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage Yu M Tan1,2, Mikkel Østergaard3, Anthony Doyle4, Nicola Dalbeth2, Maria Lobo2, Quentin Reeves4, Elizabeth Robinson5, William J Taylor6, Peter B Jones1,7, Karen Pui2, Jamie Lee1,2 and Fiona M McQueen1,2 1Department of Molecular Medicine and Pathology, University of Auckland, Park Road, Auckland 1010, New Zealand 2Department of Rheumatology, Auckland District Health Board, Greenlane West, Auckland 1051, New Zealand 3Department of Rheumatology, Copenhagen University Hospitals at Hvidovre and Gentofte, Kettegård alle 30, Hvidovre, DK-2650, Denmark 4Department of Radiology, Auckland City Hospital, Grafton Rd, Auckland 1010, New Zealand 5Department of Epidemiology and Biostatistics, University of Auckland, Morrin Road, Auckland 92019, New Zealand 6Department of Medicine, University of Otago Wellington, Mein St, Wellington 6021, New Zealand 7Department of Rheumatology, QE Health, Whakaue St, Rotorua 3010, New Zealand Corresponding author: Fiona M McQueen, [email protected] Received: 22 Sep 2008 Revisions requested: 23 Oct 2008 Revisions received: 4 Dec 2008 Accepted: 6 Jan 2009 Published: 6 Jan 2009 Arthritis Research & Therapy 2009, 11:R2 (doi:10.1186/ar2586) This article is online at: http://arthritis-research.com/content/11/1/R2 © 2009 Tan et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]